Oculis Upsized Loan Facility to Access up to CHF 100 million
Oculis (NASDAQ: OCS) has amended its loan agreement with BlackRock, significantly expanding its borrowing capacity to CHF 75 million, with potential increase to CHF 100 million. The loan comprises three tranches of CHF 25 million each, plus an additional potential CHF 25 million subject to mutual agreement.
The enhanced facility provides financial flexibility beyond current cash reserves as Oculis approaches key milestones, including FDA discussions for Privosegtor in three indications, initiation of Licaminlimab Phase 2/3 trial, and OCS-01 Phase 3 trial results. The company's current cash position extends runway into early 2028.
Oculis (NASDAQ: OCS) ha modificato il suo accordo di prestito con BlackRock, ampliando significativamente la capacit脿 di indebitamento a 75 milioni di CHF, con la possibilit脿 di aumentare fino a 100 milioni di CHF. Il prestito 猫 suddiviso in tre tranche da 25 milioni di CHF ciascuna, pi霉 un'ulteriore tranche potenziale di 25 milioni di CHF soggetta a un accordo reciproco.
La nuova linea di credito offre maggiore flessibilit脿 finanziaria oltre le riserve di cassa attuali, mentre Oculis si avvicina a traguardi importanti, tra cui le discussioni con la FDA per Privosegtor in tre indicazioni, l'avvio della sperimentazione di Licaminlimab Fase 2/3 e i risultati della sperimentazione di OCS-01 Fase 3. La posizione di cassa attuale della societ脿 garantisce liquidit脿 fino ai primi mesi del 2028.
Oculis (NASDAQ: OCS) ha modificado su acuerdo de pr茅stamo con BlackRock, ampliando significativamente su capacidad de endeudamiento a 75 millones de CHF, con un posible aumento hasta 100 millones de CHF. El pr茅stamo consta de tres tramos de 25 millones de CHF cada uno, m谩s un tramo adicional potencial de 25 millones de CHF sujeto a acuerdo mutuo.
Esta l铆nea de cr茅dito mejorada ofrece flexibilidad financiera m谩s all谩 de las reservas de efectivo actuales, mientras Oculis se acerca a hitos clave, incluyendo las discusiones con la FDA para Privosegtor en tres indicaciones, el inicio del ensayo de Licaminlimab Fase 2/3 y los resultados del ensayo de OCS-01 Fase 3. La posici贸n de efectivo actual de la compa帽铆a extiende su liquidez hasta principios de 2028.
Oculis (NASDAQ: OCS)電� BlackRock瓿检潣 雽�於� 瓿勳暯鞚� 靾橃爼頃橃棳 彀瀰 頃滊弰毳� 7,500毵� 鞀れ渼鞀� 頂勲瀾鞙茧 韥矊 頇曥灔頄堨溂氅�, 斓滊寑 1鞏� 鞀れ渼鞀� 頂勲瀾旯岇 歃濌皜頃� 靾� 鞛堨姷雼堧嫟. 雽�於滌潃 臧侁皝 2,500毵� 鞀れ渼鞀� 頂勲瀾鞚� 靹� 臧滌潣 攵勴暊旮堦臣 靸來樃 頃╈潣鞐� 霐半ジ 於旉皜 2,500毵� 鞀れ渼鞀� 頂勲瀾 攵勴暊旮堨溂搿� 甑劚霅╇媹雼�.
鞚� 臧曧檾霅� 旮堨湹 鞁滌劋鞚� 順勳灛 順勱笀 氤挫湢鞎§潉 雱橃柎靹� 鞛爼鞝� 鞙犾棸靹膘潉 鞝滉车頃橂┌, Oculis電� Privosegtor鞚� 靹� 臧�歆� 鞝侅潙歃濎棎 雽�頃� FDA 雲检潣, Licaminlimab 2/3靸� 鞛勳儊鞁滍棙 鞁滌瀾, 攴鸽Μ瓿� OCS-01 3靸� 鞁滍棙 瓴瓣臣 霌� 欤检殧 鞚挫爼響滌棎 鞝戧芳頃橁碃 鞛堨姷雼堧嫟. 須岇偓鞚� 順勳灛 順勱笀 靸來儨電� 2028雲� 齑�旯岇 鞖挫榿 鞛愱笀鞚� 頇曤炒頃╇媹雼�.
Oculis (NASDAQ : OCS) a modifi茅 son accord de pr锚t avec BlackRock, augmentant significativement sa capacit茅 d'emprunt 脿 75 millions de CHF, avec une possibilit茅 d'extension 脿 100 millions de CHF. Le pr锚t est compos茅 de trois tranches de 25 millions de CHF chacune, plus une tranche suppl茅mentaire potentielle de 25 millions de CHF soumise 脿 un accord mutuel.
Cette facilit茅 renforc茅e offre une flexibilit茅 financi猫re au-del脿 des r茅serves de tr茅sorerie actuelles, alors qu'Oculis se rapproche de jalons cl茅s, notamment les discussions avec la FDA concernant Privosegtor pour trois indications, le lancement de l'essai de Licaminlimab Phase 2/3 et les r茅sultats de l'essai OCS-01 Phase 3. La tr茅sorerie actuelle de l'entreprise assure une autonomie financi猫re jusqu'au d茅but de 2028.
Oculis (NASDAQ: OCS) hat seine Kreditvereinbarung mit BlackRock ge盲ndert und seine Kreditaufnahme erheblich auf 75 Millionen CHF erweitert, mit der M枚glichkeit einer Erh枚hung auf 100 Millionen CHF. Der Kredit besteht aus drei Tranchen zu je 25 Millionen CHF sowie einer zus盲tzlichen potenziellen Tranche von 25 Millionen CHF, die einer gegenseitigen Vereinbarung unterliegt.
Die erweiterte Kreditfazilit盲t bietet finanzielle Flexibilit盲t 眉ber die aktuellen Barreserven hinaus, w盲hrend Oculis wichtige Meilensteine erreicht, darunter FDA-Gespr盲che zu Privosegtor in drei Indikationen, den Start der Licaminlimab Phase 2/3-Studie und die Ergebnisse der OCS-01 Phase 3-Studie. Die derzeitige Liquidit盲tslage des Unternehmens sichert den Betrieb bis Anfang 2028.
- Upsized loan facility provides access to up to CHF 100 million in additional capital
- Current cash runway extends into early 2028
- Multiple near-term catalysts across three core assets in 2025-2026
- Enhanced financial flexibility with no immediate draw on the facility
- Additional debt could increase financial obligations
- Loan agreement terms and interest rates not disclosed
Insights
Oculis secures expanded CHF 100M loan facility, extending runway to early 2028 and supporting advancement of three core clinical programs.
Oculis has significantly strengthened its financial position by upsizing its loan agreement with BlackRock, providing access to
The financing enhancement is strategically timed to support multiple near-term clinical milestones across Oculis' pipeline, including:
- FDA regulatory discussions for Privosegtor (OCS-05) across three indications in H2 2025
- Initiation of Licaminlimab (OCS-02) Phase 2/3 trial for dry eye disease in H2 2025
- Launch of Privosegtor Phase 2/3 trial for acute optic neuritis in H1 2026
- OCS-01 Phase 3 DIAMOND trial readouts in Q2 2026, potentially leading to an NDA filing in H2 2026
What's particularly notable is that no amounts were drawn at signing, indicating this facility functions as financial insurance rather than immediate operational funding. Management reports their current cash position already provides runway into early 2028, with this facility serving as additional flexibility.
This financial maneuver strengthens Oculis' negotiating position as they approach critical clinical and regulatory milestones. The expanded facility gives them operational latitude to pursue optimal development strategies without capital constraints potentially forcing compromises. For a clinical-stage biopharmaceutical company with multiple programs advancing toward late-stage development and potential commercialization, securing this additional financial backstop without immediate dilution represents prudent capital management.
ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (鈥淥culis鈥� or the 鈥淐ompany鈥�), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the 鈥淎mended Loan Agreement鈥�) with funds and accounts managed by BlackRock (the 鈥淟ender鈥�).
The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, and the upsized structure will provide CHF 75.0 million in borrowing capacity (which may be increased to up to CHF 100.0 million) (the 鈥淟oan鈥�).聽 The Loan comprises tranches 1, 2 and 3, in the amounts of CHF 25.0 million each, as well as an additional loan of up to CHF 25.0 million, which may be made available by the Lender to Oculis on mutually agreed terms.聽 No amounts were drawn at signing.
Access to this additional capital offers significant financial flexibility beyond Oculis鈥� current cash reserves as the Company moves toward upcoming key milestones across all three core assets: regulatory discussions with the FDA on three indications investigated with Privosegtor (OCS-05) for acute optic neuritis, non-arteritic anterior ischemic optic neuritis (NAION), and treatment of acute relapses in multiple sclerosis (MS) during 2H 2025; initiation of Licaminlimab (OCS-02) Phase 2/3 trial for dry eye disease in 2H 2025; initiation of Privosegtor (OCS-05) Phase 2/3 trial for acute optic neuritis in 1H 2026; OCS-01 Phase 3 DIAMOND trials鈥� topline results in Q2 2026, and if positive, its first NDA filing in 2H 2026.
Riad Sherif, M.D., Chief Executive Officer of Oculis, said, 鈥淲e are pleased to have upsized our previous loan agreement with funds and accounts managed by BlackRock, which expands an instrument allowing enhanced flexibility to ensure the future financial and operational strength of Oculis. Our current robust cash position provides runway into early 2028, which is further strengthened by the loan facility, as we remain focused on advancing our portfolio of differentiated assets and bringing transformative treatments to those who need them most.鈥澛�
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis鈥� highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a first-in-class neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel, first-in-class topical anti-TNF伪 in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit:
Oculis Contacts
Ms. Sylvia Cheung, CFO
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the future drawdowns of the Loan, the expected use of proceeds from the Loan, the Company鈥檚 expected financial position and cash runway timing, the progress and results of current and future clinical trials, Oculis鈥� research and development programs, regulatory and business strategy, including planned interactions with the FDA; Oculis鈥� future development plans; and the timing or likelihood of regulatory filings and approvals are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis鈥� control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those outlined in the Risk Factors section of Oculis鈥� annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�). Copies of these documents are available on the SEC鈥檚 website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
FAQ
What is the new loan facility amount for Oculis (OCS)?
How long does Oculis' (OCS) current cash runway extend?
What are the key upcoming milestones for Oculis (OCS)?
Who is providing the loan facility to Oculis (OCS)?
Has Oculis (OCS) drawn any amounts from the new loan facility?
